This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Elutia, Inc.
11/5/2026
Good day. Thank you for standing by. Welcome to the Lucia third quarter 2026 financial results call. At this time, all participants are in a listen-only mode. After the speaker's presentation, we'll open up for questions. To ask a question during the session, you need to press star 101 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 101 again. Please be advised that today's call is being recorded. I would now like to hand it over to our first speaker, Bernadine Czerniak. Please go ahead.
Thank you, operator, and thank you all for participating in today's call. Earlier today, Illusia released financial results for the third quarter ended September 30th, 2026. A copy of their press release is available on the company's website. Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the federal securities laws which are pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that do not relate to matters of historical facts or relate to expectations or predictions of future events, results, or performance are forward-looking statements. All forward-looking statements, including without limitation, those relating to our operating trends and future financial performance are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materialize differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For lists and descriptions of the risks and uncertainties associated with our business, please refer to the Risk Factors section of our public filings with the SEC, including Alusha's annual report on Form 10-K for the year ended December 31, 2025, and in our subsequent periodic reports on Form 10-Q and current reports on Form 8-K, accessible on the SEC's website at www. Thank you for joining us. Thank you, Bernadine, and thank you all for joining us today.
It is an exceptionally busy and exciting time for us at Lucia and I'm eager to get you up to speed on our progress. Here's how we'll spend our time. First, the need. It is serious and the lack of attention being paid to it by industry is astonishing. Infection was a major focus at last month's meeting of the American Society of Plastic Surgeons in Houston. It came up in every one of the 11 breast research sessions yet there were no commercial products addressing it and no company on the exhibit floor was talking about a solution. That market dislocation has created a tremendous opportunity for Ellucia. Second, we'll review the great progress the team is making on NXT 41X. Our key GLP antimicrobial study met its predetermined endpoints. Surgeon feedback on the actual product was very favorable and NXT 41X is set to head to FDA this quarter. Then Matt will walk you through how we funded ourselves through LAUNCH without an equity offering. He'll also cover our cardiovascular business and its remarkable growth, take you through the third quarter results and end with the milestones ahead. Then we'll open the line for your questions including the milestones ahead, no, including and some that were actually brought in by you. Let me start with the need because that is where everything at Alusha begins. Infection in plastic and reconstructive surgery is common. It is serious and it remains unsolved. Over the next few slides, I'll show you what surgeons themselves presented on at this year's national meeting because their data and insights make the case better than we ever could. The ASPS meeting was in Houston last month, and to me, one of the most astonishing things that stood out above the rest was infection. There were 11 scientific sessions devoted to breast research. Infection risk and prevention were discussed in every one of them. Of the 135 research presentations, 70, or 52%, addressed infection. Infection wasn't only covered in the research sessions, however. The conference included an entire course called 28 Years Later, Current Strategies in Salvaging the Infected Implant. Think about that. Surgeons have been fighting implant infection for decades, and it is still one of the biggest problems plastic and reconstructive surgeons face today. The data presented at the meeting were sobering. Investigators from UCSF reported on 1,094 breasts that underwent immediate implant-based surgery. In women who did not receive chemotherapy before surgery, 17.6 developed an infection. In women who did, it was 23%. That is nearly one in four. A second study, from Miami Cancer Institute looked at 419 breasts. Every one of those patients received antibiotics before and after surgery, and 19.3% still developed an infection. These are leading centers following current best practices, and infection still approaches one in four. And in most cases, These are women who are already fighting cancer. Think about that. So why not just do what we normally do and give patients more antibiotics? Because it doesn't work. A 20-year multi-center study presented at the meeting answered that question definitively. It looked at 4,647 patients across 170 countries. Healthcare Organizations. Extending antibiotics past 24 hours did not reduce infection at 30 days, 60 days, or 90 days. And the biology explains why. Systemic antibiotics travel through the blood. A mastectomy closes off the very blood vessels that would carry those drugs to the surgical site. You can give more drug, but it can't get to where it needs to go. Which brings me back to what struck me most in Houston. In the session rooms, in the hallways, at the receptions, surgeons were focused on infection. 70 presentations across all 11 breast research sessions. Then I walk into the exhibit floor and found a sea of commodity surgical matrices. There were literally 25 on the market and none are demonstrably different from the next. But no commercial offering for infection. No one was even talking about it. On one side, you have surgeons and their patients living with this problem. On the other, an industry that hasn't offered them a solution. That gap is the unmet need. It is the reason Aleutia exists and it is exactly what we intend to fix. with NXT 41X. Now let me turn to how we intend to close that gap. NXT 41X is our lead drug delivery program. Our key GLP study is complete, our manufacturing is set for commercial production, and we plan to submit NXT 41X to FDA this quarter. Let me walk you through where our programs stand. We currently have two product development programs and both are on track. I want to be clear that they are on separate submissions on independent timelines. First, NXT 41, our biological surgical matrix without drug. The 510K is submitted, the review is progressing as expected, and we anticipate a clearance decision this quarter and we have every reason to believe it will be favorable. However, it is largely academic at this point. NXT 41 has already done its job, which was to discover and answer FDA's questions about the base matrix. We have no intention of commercializing NXT 41. It broke the regulatory ice for NXT 41X. and everything that we learned from it has been built into the NXT 41X platform. The more material submission is NXT 41X, our lead drug delivery program. Our key GLP study met its predetermined endpoints and we plan to submit NXT 41X to FDA this quarter. From there, we anticipate a clearance decision in the second quarter of 2027, a commercial soft launch in the second half of 2027, and a full commercial launch in 2028. That timing reflects our current expectations and is, of course, subject to FDA review. But all in all, it is a very busy but exciting time in R&D and regulatory. This is the study that supports our submission, and it is pretty cool. In a GLP rabbit implant study, NXT41X met its pre-specified performance endpoints. We challenged it with MRSA, a drug-resistant gram-positive form of the most common pathogen in breast surgery, Staph aureus. And we then challenged it with E. coli, a particularly nasty gram-negative rod that can cause serious infection and lead to sepsis. And we didn't make this easy. We put the bacteria on the uncoated side of the matrix, away from the drug. And we added a lot of them. The MRSA challenge was eight logs. That is 100 million bacteria. The E. coli challenge was six logs, a million bacteria. Both represent far more contamination than would normally be present in the operating room, creating true worst-case conditions. So the results? After seven days of implantation, we recovered zero viable bacteria from the NXT41X samples and surrounding tissue, zero. Contrast that with the matrix without antibiotics. Every animal implanted with the matrix alone developed fulminant colonization by those same pathogens. Zero versus 100%. Pretty cool. Data matter, but the surgeon's opinion matters too, since they are the ultimate decision maker. While we were in Houston, our NXT 41X Surgeon Steering Committee met in person and their feedback on the design, handling, and performance of NXT 41X was both informative and very positive. And while we talked about a number of different product attributes, two really stood out as the difference makers. And I wanted to share them with you since this is how a surgeon takes a look at a product like 41X. They put it simply, it's about the drug being in the right place at the right time. The right place to them means powerful antibiotics that are uniformly distributed across the entire surgical site. That's exactly where systemic antibiotics fail to reach. The right time means 30 days of coverage. Why? Because that carries them through drain removal which usually happens somewhere around day 17. It was simple and it was a powerful message for us to hear and it was gratifying for the team since that's what we designed NXT 41X to do. And we're ready to make it. Our automated drug coding system is set for commercial production. It gives us at least $300 million in revenue capacity at launch and is designed to support a gross margin above 80% at scale. That matters for two obvious reasons. First, we certainly don't want to be supply constrained as the product is launching. Second, we want to be able to make money with this product, and the margin profile we wanted was built into the manufacturing process from day one. So when you take a step back and you look at it, I hope you can see what we're creating here. A product for a true unmet medical need. One that already has been proven with our own technology, that our own technology can answer, and one that we can make money with. And we have the capital and team and intellectual property to see it through. And with that, I'll turn it over to Matt to close out and then be back with you for Q&A.
You're reading a preview of the ELUT Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing